secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viracta Therapeutics, Inc. (—)
CIK:        0001061027
Form:       8-K
Filed at:   2023-11-17T23:59:59+00:00
Accession:  0000950170-23-064914
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Viracta receives Nasdaq minimum bid price deficiency notice; 180 days to cure
-----------------------------------------------------------------------------

- Nasdaq notified Viracta on Nov 15, 2023 that its common stock closing bid price was below $1.00 for 30 consecutive business days.
- Company has until May 13, 2024 to regain compliance by closing at $1.00 or more for 10 consecutive business days.
- If not compliant by May 13, Viracta may transfer to Nasdaq Capital Market and receive an additional 180-day cure period.
- The deficiency notice has no immediate impact on trading; Viracta will monitor bid price and consider available remedies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061027/000095017023064914/0000950170-23-064914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061027/000095017023064914/virx-20231115.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-064914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer